Now Open:
Funded Clinical Trial for Dogs with Malignant Tumors

Trial Summary

A clinical trial to evaluate a novel anti-cancer therapy is now available. The study is designed into two phases. The initial phase will evaluate the safety of this drug in dogs with any measurable cancer (excluding hemangiosarcoma). The 2nd phase will evaluate the safety of this drug in dogs with hemangiosarcoma exclusively. No placebo is used.

In both phases, dogs will receive the study drug as daily, oral treatment with evaluations performed once weekly for the first 28 days, then once monthly. Blood sample collection and tumor biopsies are collected throughout the study to assess the metabolism and biological activity of this drug. Dogs with hemangiosarcoma will not receive biopsies.

During the course of the study, dogs will not be allowed any holistic therapy, chemotherapy, or other investigational therapies unless approved by the investigator and the sponsor.

Trial Support and Funding

Study drug, diagnostic tests, and follow-up exams will be paid for by the study sponsor. In the event that side effects are attributed to the study drug, the study will pay for medical management of the side effects.

Trial Eligibility

Client-owned pet dogs that meet the following criteria:

• Histological or cytological diagnosis of cancer – excluding hemangiosarcoma in the first phase of the study;
• Measurable cancer that is amenable to serial biopsy;
• Generally feeling well;
• Prior treatment with chemotherapy accepted but a washout of 21 days is required;
• Prior treatment with non-steroidal anti-inflammatory drugs (NSAID) and prednisone accepted but a 14-day washout is required;
• Prior treatment with radiation therapy is accepted but a 30-day washout is required;
• No prior small molecule inhibitors (i.e. Palladia™);
• No prior immunotherapy (i.e. Melanoma Vaccine);